Page last updated: 2024-11-11

nidulin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nidulin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6450195
CHEMBL ID3358704
SCHEMBL ID5805959
SCHEMBL ID16435037
MeSH IDM0052615

Synonyms (22)

Synonym
o-methylustin
1329-04-0
11h-dibenzo(b,e)(1,4)dioxepin-11-one, 2,4,6(or 2,4,7)-trichloro-3-hydroxy-8-methoxy-1,9-dimethyl-7(or 6)-(1-methyl-1-propenyl)-
nidulin
1-[(e)-but-2-en-2-yl]-2,8,10-trichloro-9-hydroxy-3-methoxy-4,7-dimethylbenzo[b][1,4]benzodioxepin-6-one
SCHEMBL5805959
4,2-cresotic acid, 3,5-dichloro-6-(5-chloro-2-hydroxy-4-methoxy-6-(1-methylpropenyl)-m-tolyloxy)-, epsilon-lactone
unii-5zeg4ds0u1
4,2-cresotic acid, 3,5-dichloro-6-(5-chloro-2-hydroxy-4-methoxy-6-(1-methylpropenyl)-m-tolyloxy)-, .epsilon.-lactone
11h-dibenzo(b,e)(1,4)dioxepin-11-one, 2,4,7-trichloro-3-hydroxy-8-methoxy-1,9-dimethyl-6-(1-methyl-1-propenyl)-, (e)-
nidulin [mi]
ustin methyl ether
5ZEG4DS0U1 ,
methylustin
1402-15-9
J-000245
SCHEMBL16435037
CHEMBL3358704
2,8,10-trichloro-9-hydroxy-3-methoxy-4,7-dimethyl-1-[(e)-1-methylprop-1-enyl]benzo[b][1,4]benzodioxepin-6-one
DTXSID501017592
Q27263102
AKOS040755905
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1753911Cytotoxicity against African green monkey Vero cells by colorimetric assay
AID1753906Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed as bacterial growth inhibition incubated for 18 hrs by CLSI protocol based agar microdilution method
AID1753907Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as bacterial growth inhibition incubated for 18 hrs by CLSI protocol based agar microdilution method
AID1753909Antifungal activity against Cryptococcus neoformans ATCC 90113 assessed as fungal growth inhibition incubated for 24 to 48 hrs by CLSI protocol based agar microdilution method
AID1753915Antifungal activity against Cryptococcus neoformans ATCC 90113 assessed as fungal growth inhibition by CLSI protocol based assay
AID1753908Antifungal activity against Candida albicans NCPF 90028 assessed as fungal growth inhibition incubated for 24 to 48 hrs by CLSI protocol based agar microdilution method
AID1753917Cytotoxicity against African green monkey Vero cells incubated for 24 hrs by MTT assay
AID1753912Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed as bacterial growth inhibition by CLSI protocol based assay
AID1753913Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as bacterial growth inhibition by CLSI protocol based assay
AID1753921Antifungal activity against Microsporum gypseum assessed as fungal growth inhibition at 50 ug/ml by CLSI protocol based assay
AID1753910Antifungal activity against Microsporum gypseum assessed as fungal growth inhibition incubated for 4 days by CLSI protocol based agar microdilution method
AID1174113Antimycobacterial activity against Mycobacterium tuberculosis H37Ra after 7 days by microplate Alamar blue assay2015European journal of medicinal chemistry, Jan-07, Volume: 89Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis.
AID1753920Antifungal activity against Candida albicans NCPF 90028 assessed as fungal growth inhibition at 50 ug/ml by CLSI protocol based assay
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (33.33)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (50.00)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.01 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]